Breaking News

Onyx Completes API Project

May 13, 2014

Provided process development and production of Neuronascent’s lead candidate NNI-362

Onyx Scientific has completed a development and API manufacturing project to support Neuronascent’s pre-IND submission. Onyx provided process development and production of a 1kg batch of API along with supporting initial stability data for Neuronascent’s lead candidate NNI-362 for the potential treatment of Alzheimer’s and Parkinson’s disease and other neurodegenerative disorders. 
Onyx Scientific’s UK-based labs focus on challenging chemistry for early stage programs, along with scale-up and tech transfer using its commercial manufacturing sites in India.
Judith Kelleher-Andersson, Ph.D., founder, president and chief executive officer at Neuronascent said, “Onyx Scientific has the ability to synthesize high quality API, while still taking into account the time and financial concerns of a small biotech company.We have had a very positive experience in dealing with the entire Onyx Scientific team and they have played an important role in moving our Alzheimer’s disease project forward.” 
Denise Bowser, commercial director at Onyx Scientific, said, “We thoroughly enjoyed working with the team at Neuronascent and were able to deliver their project on time despite a pretty tight deadline.Early stage development and small scale manufacture of API has been our sweet spot for many years but we continue to improve to ensure we are meeting the needs of our clients across the world who are dealing with increased pressure to develop new products quicker than ever.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.